The Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) market was valued at US$ 98.6 million in 2024 and is projected to reach US$ 147.2 million by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.9% during the forecast period (2024-2030). This expansion is driven by increasing applications in drug delivery systems, tissue engineering, and medical devices across the region’s rapidly developing healthcare sector.
PLGA has emerged as a critical biomaterial due to its unique properties of biocompatibility and controlled biodegradability. With Japan leading the market (40% share) followed by China (30%) and South Korea (20%), this region is becoming a global hub for advanced medical polymer development. This blog examines the Top 10 PLGA Companies in Asia Pacific that are shaping the future of medical materials innovation.
🔟 10. Durect Corporation
Headquarters: Cupertino, California, USA (Asia Pacific subsidiary)
Key Offering: Proprietary PLGA drug delivery technologies
Durect delivers specialized PLGA-based sustained release platforms to Asian pharmaceutical companies, with its SABER® technology enabling long-acting injectable formulations. The company has established clinical partnerships across Japan and China.
Technology Advantages:
- FDA-approved depot drug delivery systems
- Customized PLGA formulations for regional needs
- Technical transfer services for Asian partners
9️⃣ 9. Sinopharm International Corporation
Headquarters: Beijing, China
Key Offering: Vaccine-grade PLGA polymers
As part of China’s largest pharmaceutical conglomerate, Sinopharm provides PLGA excipients for domestic vaccine production, supporting China’s pharmaceutical independence strategy with locally sourced biomaterials.
Strategic Focus:
- PLGA adjuvants for novel vaccine platforms
- GMP-certified Asian production facilities
- Expanding into Southeast Asian biotech markets
Download FREE Sample Report:
Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) Market – View in Detailed Research Report
8️⃣ 8. PolySciTech (A division of Akina, Inc.)
Headquarters: West Lafayette, Indiana, USA (Asia Pacific operations)
Key Offering: Research-grade PLGA materials
PolySciTech serves Asia’s academic and pharmaceutical research sectors with precisely characterized PLGA polymers, supporting early-stage drug development across the region’s growing biotech ecosystem.
Research Support:
- 150+ PLGA formulations available
- Japan/Korea-focused distribution network
- GMP capabilities for clinical trial materials
7️⃣ 7. Shanghai New Shangshang Biomaterial Co., Ltd.
Headquarters: Shanghai, China
Key Offering: Medical-grade PLGA formulations
This specialized Chinese manufacturer develops PLGA products for surgical applications, including absorbable sutures and implant coatings, with quality systems meeting international medical device standards.
Quality Certifications:
- ISO 13485 certified production
- CE marked medical device polymers
- FDA Drug Master Files for key products
6️⃣ 6. Hangzhou Xianhe Plastic Co., Ltd.
Headquarters: Hangzhou, China
Key Offering: Industrial and pharmaceutical PLGA
From its roots in conventional plastics, Hangzhou Xianhe has grown into a biomaterials specialist, supplying PLGA to China’s booming pharmaceutical packaging and medical device sectors.
Production Capabilities:
- 5000+ ton annual polymer capacity
- Pharma-grade clean room facilities
- Custom molecular weight formulations
Download FREE Sample Report:
Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) Market – View in Detailed Research Report
5️⃣ 5. Shenzhen Esun Industrial Co., Ltd.
Headquarters: Shenzhen, China
Key Offering: 3D printing PLGA materials
Esun Industrial leads China’s biomaterial additive manufacturing sector with specialized PLGA filaments and powders for medical 3D printing applications, from surgical models to patient-specific implants.
Innovation Highlights:
- Patented PLGA-thermoplastic blends
- Collaborations with medical 3D printing firms
- Expanding ASEAN market presence
4️⃣ 4. Anhui Anke Biotechnology (Group) Co., Ltd.
Headquarters: Hefei, China
Key Offering: Pharmaceutical excipient PLGA
Anhui Anke has become a trusted PLGA supplier for China’s generic drug industry, providing consistent, pharmacopeia-compliant polymers for controlled release formulations.
Regulatory Compliance:
- Multiple DMF submissions
- China GMP certification
- 25+ PLGA drug formulation approvals
3️⃣ 3. Jinan Daigang Biomaterial Co., Ltd.
Headquarters: Jinan, China
Key Offering: Specialty PLGA copolymers
Jinan Daigang excels in customized PLGA formulations, offering over 15 distinct lactide-glycolide ratios to meet precise drug delivery and medical device requirements.
Technical Expertise:
- Advanced polymer characterization lab
- Strict endotoxin control (<0.25 EU/mg)
- Custom degradation profile development
2️⃣ 2. Corbion N.V.
Headquarters: Amsterdam, Netherlands (Asia Pacific facilities)
Key Offering: Purasorb® PLGA polymers
Corbion brings European biomaterial expertise to Asia through its high-purity PLGA product line, supported by local technical centers and warehousing to serve regional customers.
Asian Market Strengths:
- Singapore applications laboratory
- Japan/Korea regulatory support team
- China-licensed medical grade production
1️⃣ 1. Evonik Industries AG
Headquarters: Essen, Germany (Asian operations center in Shanghai)
Key Offering: RESOMER® brand PLGA
Evonik dominates the Asia Pacific PLGA market with its comprehensive RESOMER® portfolio, supplying the region’s pharmaceutical and medical device manufacturers from local production facilities.
Market Leadership:
- 40+ approved PLGA-based drug products
- Joint development projects in Japan/Korea
- Shanghai-based technical support center
Get Full Report Here:
Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) Market – View in Detailed Research Report
🔬 Future Outlook: PLGA’s Expanding Role in Asia Pacific Healthcare
The Asia Pacific PLGA market is poised for accelerated growth as healthcare systems increasingly adopt advanced biomaterial solutions. With drug delivery systems accounting for 65% of current PLGA consumption, the material is becoming fundamental to modern medical treatment.
📈 Key Industry Developments:
- Japan maintaining technology leadership with 40% market share
- 25% increase in clinical trials using PLGA drug formulations
- 15% annual growth in oncology-targeted PLGA applications
- 20% R&D investment increase for medical-grade polymers
Get Full Report Here:
Asia Pacific Poly(Lactic-Co-Glycolic Acid) (PLGA) Market – View in Detailed Research Report
These top PLGA companies are not just supplying materials—they’re enabling Asia Pacific’s transformation into a global hub for advanced biomedical solutions.
